The STAR trial will begin enrolling in 2015 and will include 80 patients, in up to 12 centers in the United States. The trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of a single administration of Cytori's lead cellular therapeutic, ECCS-50, in scleroderma patients with hand dysfunction. MarketWatch, 01/12/2015. (Also see: Scleroderma Clinical Trials: ADRC Injections/STAR)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.